Roth Capital assumed coverage on shares of Cogentix Medical, Inc. (NASDAQ:CGNT) in a research report report published on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $4.00 price target on the medical device company’s stock.

Several other equities analysts also recently weighed in on the company. JMP Securities initiated coverage on Cogentix Medical in a research report on Friday, October 6th. They issued an outperform rating and a $5.00 target price for the company. Zacks Investment Research raised Cogentix Medical from a hold rating to a buy rating and set a $2.50 target price for the company in a research report on Friday, August 4th.

Cogentix Medical (CGNT) traded down $0.03 during midday trading on Wednesday, reaching $2.60. The company’s stock had a trading volume of 54,300 shares, compared to its average volume of 54,101. Cogentix Medical has a 52 week low of $1.55 and a 52 week high of $3.26.

WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/11/12/roth-capital-initiates-coverage-on-cogentix-medical-inc-cgnt.html.

Several institutional investors have recently made changes to their positions in CGNT. Renaissance Technologies LLC grew its position in shares of Cogentix Medical by 2.3% during the first quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock worth $1,013,000 after buying an additional 12,459 shares in the last quarter. Northern Trust Corp grew its position in shares of Cogentix Medical by 0.4% during the second quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock worth $129,000 after buying an additional 326 shares in the last quarter. Finally, Broadfin Capital LLC lifted its stake in Cogentix Medical by 45.2% during the second quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock worth $1,905,000 after purchasing an additional 340,771 shares during the last quarter. 12.51% of the stock is owned by institutional investors and hedge funds.

Cogentix Medical Company Profile

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.